Pivotal readout

Sinovent's funobactam combination matches relebactam regimen in hospital pneumonia

A phase 3 double-blind trial of Sinovent's imipenem-cilastatin-funobactam in hospital-acquired and ventilator-associated bacterial pneumonia has been published in a leading infectious disease journal. The combination was non-inferior to imipenem-cilastatin-relebactam on 14-day all-cause mortality, with good tolerability. Sinovent positions it as a domestic option against carbapenem-resistant Gram-negative bacteria.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call